Literature DB >> 19368529

Structure-activity analysis of aging and reactivation of human butyrylcholinesterase inhibited by analogues of tabun.

Eugénie Carletti1, Nadine Aurbek, Emilie Gillon, Mélanie Loiodice, Yvain Nicolet, Juan-Carlos Fontecilla-Camps, Patrick Masson, Horst Thiermann, Florian Nachon, Franz Worek.   

Abstract

hBChE [human BChE (butyrylcholinesterase)] naturally scavenges OPs (organophosphates). This bioscavenger is currently in Clinical Phase I for pretreatment of OP intoxication. Phosphylated ChEs (cholinesterases) can undergo a spontaneous time-dependent process called 'aging' during which the conjugate is dealkylated, leading to creation of an enzyme that cannot be reactivated. hBChE inhibited by phosphoramidates such as tabun displays a peculiar resistance to oxime-mediated reactivation. We investigated the basis of oxime resistance of phosphoramidyl-BChE conjugates by determining the kinetics of inhibition, reactivation (obidoxime {1,1'-(oxybis-methylene) bis[4-(hydroxyimino) methyl] pyridinium dichloride}, TMB-4 [1,3-trimethylene-bis(4-hydroxyiminomethylpyridinium) dibromide], HLö 7 {1-[[[4-(aminocarbonyl) pyridinio]methoxy]methyl]-2,4-bis-[(hydroxyimino)methyl] pyridinium dimethanesulfonate)}, HI-6 {1-[[[4-(aminocarbonyl) pyridinio] methoxy] methyl]-2-[(hydroxyimino)methyl]pyridinium dichloride monohydrate} and aging, and the crystal structures of hBChE inhibited by different N-monoalkyl and N,N-dialkyl tabun analogues. The refined structures of aged hBChE conjugates show that aging proceeds through O-dealkylation of the P(R) enantiomer of N,N-diethyl and N-propyl analogues, with subsequent formation of a salt bridge preventing reactivation, similarly to a previous observation made on tabun-ChE conjugates. Interestingly, the N-methyl analogue projects its amino group towards the choline-binding pocket, so that aging proceeds through deamination. This orientation results from a preference of hBChE's acyl-binding pocket for larger than 2-atoms linear substituents. The correlation between the inhibitory potency and the N-monoalkyl chain length is related to increasingly optimized interactions with the acyl-binding pocket as shown by the X-ray structures. These kinetics and X-ray data lead to a structure-activity relationship that highlights steric and electronic effects of the amino substituent of phosphoramidate. This study provides the structural basis to design new oximes capable of reactivating phosphoramidyl-hBChE conjugates after intoxication, notably when hBChE is used as pretreatment, or to design BChE-based catalytic bioscavengers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368529     DOI: 10.1042/BJ20090091

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  14 in total

1.  Direct quantitation of methyl phosphonate adducts to human serum butyrylcholinesterase by immunomagnetic-UHPLC-MS/MS.

Authors:  Melissa D Carter; Brian S Crow; Brooke G Pantazides; Caroline M Watson; Jerry D Thomas; Thomas A Blake; Rudolph C Johnson
Journal:  Anal Chem       Date:  2013-11-08       Impact factor: 6.986

2.  Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics.

Authors:  Ivan Smirnov; Eugénie Carletti; Inna Kurkova; Florian Nachon; Yvain Nicolet; Vladimir A Mitkevich; Hélène Débat; Bérangère Avalle; Alexey A Belogurov; Nikita Kuznetsov; Andrey Reshetnyak; Patrick Masson; Alexander G Tonevitsky; Natalia Ponomarenko; Alexander A Makarov; Alain Friboulet; Alfonso Tramontano; Alexander Gabibov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

Review 3.  Efforts toward treatments against aging of organophosphorus-inhibited acetylcholinesterase.

Authors:  Qinggeng Zhuang; Amneh Young; Christopher S Callam; Craig A McElroy; Özlem Dogan Ekici; Ryan J Yoder; Christopher M Hadad
Journal:  Ann N Y Acad Sci       Date:  2016-06-21       Impact factor: 5.691

4.  Structural study of the complex stereoselectivity of human butyrylcholinesterase for the neurotoxic V-agents.

Authors:  Marielle Wandhammer; Eugénie Carletti; Marcel Van der Schans; Emilie Gillon; Yvain Nicolet; Patrick Masson; Maurice Goeldner; Daan Noort; Florian Nachon
Journal:  J Biol Chem       Date:  2011-03-23       Impact factor: 5.157

Review 5.  Resurrection and Reactivation of Acetylcholinesterase and Butyrylcholinesterase.

Authors:  Andrew J Franjesevic; Sydney B Sillart; Jeremy M Beck; Shubham Vyas; Christopher S Callam; Christopher M Hadad
Journal:  Chemistry       Date:  2019-02-13       Impact factor: 5.236

6.  Cocrystallization studies of full-length recombinant butyrylcholinesterase (BChE) with cocaine.

Authors:  Oluwatoyin Ajibola Asojo; Oluyomi Adebola Asojo; Michelle N Ngamelue; Kohei Homma; Oksana Lockridge
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-03-24

7.  High-Confidence Qualitative Identification of Organophosphorus Nerve Agent Adducts to Human Butyrylcholinesterase.

Authors:  Thomas P Mathews; Melissa D Carter; Darryl Johnson; Samantha L Isenberg; Leigh Ann Graham; Jerry D Thomas; Rudolph C Johnson
Journal:  Anal Chem       Date:  2017-01-24       Impact factor: 6.986

8.  Why does the G117H mutation considerably improve the activity of human butyrylcholinesterase against sarin? Insights from quantum mechanical/molecular mechanical free energy calculations.

Authors:  Yuan Yao; Junjun Liu; Chang-Guo Zhan
Journal:  Biochemistry       Date:  2012-10-23       Impact factor: 3.162

Review 9.  Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior.

Authors:  Patrick Masson; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2009-12-11       Impact factor: 4.013

10.  Mass spectrometry method to identify aging pathways of Sp- and Rp-tabun adducts on human butyrylcholinesterase based on the acid labile P-N bond.

Authors:  Wei Jiang; John R Cashman; Florian Nachon; Patrick Masson; Lawrence M Schopfer; Oksana Lockridge
Journal:  Toxicol Sci       Date:  2013-01-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.